Jianbo Yue's research focuses on cell signaling related to autophagy, endosomal trafficking, metastasis, anticancer immunity, Ca2+ and reactive oxygen species (ROS). His research group established a high-content drug screening platform, and identified and/or synthesized many potent and specific modulators of autophagy or/and endosomal trafficking. His group also established both cell and animal models to evaluate the ability of these compounds to modulate viral infection, tumor metastasis and anti-cancer immunity. Jianbo founded two Biotech startup companies (6J Biotech and VBT Biotech), focusing on developing novel anti-metastatic or antiviral drugs, respectively.
Yue has been actively participating in undergraduate and graduate teaching. At DKU (2022-), he teaches Experimental Methods in Functional Genomics (BIOL403) and Integrated Biology (BIOL110). At the City University of Hong Kong (2014-2022), he taught Cellular Pathology, Molecular Biology of the Cell, Hematology, and Animal Physiology. At the University of Hong Kong (2008-2014), he taught Physiology & Pathophysiology, and Cell Biology.
Jianbo graduated from Sichuan University with a B.Sc. degree in biochemistry (1987-1991), Peking University with an M.Sc. degree in genetics (1991-1994) and Pennsylvania State University with a Ph.D. degree in pharmacology (1995-2000). After postdoc training at Stanford University (2001-2017), he moved to the University of Hong Kong to start his independent academic career as an assistant professor in the Department of Physiology. He later joined the City University of Hong Kong as an associate professor in the Department of Biomedical Sciences.